Drug Profile
Granulocyte colony-stimulating factor - Takeda
Alternative Names: G-CSF - Takeda; G-CSF - Transkaryotic Therapies; Gene-activated G-CSF; Gene-activated granulocyte colony-stimulating factorLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Class
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 02 May 2007 No development reported - Phase-I for Neutropenia in USA (Injection)
- 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group